| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8773849 | Kidney International Reports | 2018 | 12 Pages |
Abstract
We propose mTORC1 inhibition as an effective treatment option for patients with sporadic AML, which represents the vast majority of patients with this tumor.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Oren Pleniceanu, Dorit Omer, Einat Azaria, Orit Harari-Steinberg, Benjamin Dekel,